In particular, the study attrition was not explained clearly in all studies and study confounders and statistical analysis were also uncertain. assessed from the Marks of Recommendation, Assessment, Development and Evaluation system. Results Out of 4603 records retrieved nine studies were included in this review. All studies contained some risk of bias. Based on pooled data myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) was significantly associated with microscopic polyangiitis incidence with risk percentage (RR) of 20.2 (95% CI: 7.22 to 56.4) and antinuclear antibody (ANA) was also significantly Catechin associated with the development of connective cells diseases with RR of 7.11 (p=0.001) (10 instances in 157 individuals with ANA) in one study. However, there was no significant association of autoantibodies with all-cause mortality aside from MPO-ANCA and proteinase 3-ANCA in one study each. MPO-ANCA was not demonstrated to be associated with all-cause mortality by meta-analysis. The quality of evidence was deemed as either low or very low. Conclusions The presence of autoantibodies such as MPO-ANCA and ANA was demonstrated Catechin to be associated with the development of some autoimmune diseases for individuals with IPF although there was no difference of all-cause mortality. However, the results should be interpreted with extreme caution due to low evidence level. PROSPERO registration quantity CRD42017077336. (2013)29 Medium risk High risk Medium riskLow risk High risk High risk Lee (2013)13 Medium risk High risk Low riskLow risk High risk Medium riskMoua (2014)30 Low risk High risk Medium riskLow riskLow risk High risk Song (2009)31 High risk High risk High risk Low risk High risk High risk Kagiyama (2015)32 Medium risk High risk Low riskLow risk High risk High risk Hosoda (2016)33 Low risk High risk Low riskLow riskMedium risk High risk Nozu (2009)34 High risk High risk Low riskLow riskMedium risk High risk Hozumi (2016)35 Medium risk High risk Low riskLow riskMedium risk High risk Hozumi (2018)36 High risk High risk Medium riskLow riskMedium risk High risk Open in a separate window *Text in bold referring to high risk of bias. Univariate analysis All-cause mortality Among varied autoantibodies tested, the effect of ANA and RF on all-cause mortality was reported separately in two studies. Kang (2013)29 Median survival time (2015)32 HR 1.31 (0.98 to 1 1.76)C?RF (20?IU/mL)Kang Mouse monoclonal to CD13.COB10 reacts with CD13, 150 kDa aminopeptidase N (APN). CD13 is expressed on the surface of early committed progenitors and mature granulocytes and monocytes (GM-CFU), but not on lymphocytes, platelets or erythrocytes. It is also expressed on endothelial cells, epithelial cells, bone marrow stroma cells, and osteoclasts, as well as a small proportion of LGL lymphocytes. CD13 acts as a receptor for specific strains of RNA viruses and plays an important function in the interaction between human cytomegalovirus (CMV) and its target cells (2013)29 Median survival time (2015)32 HR 1.16 (0.83 to 1 1.61)C?MPO-ANCAKagiyama (2015)32 HR 1.65 (0.97 to 2.80)HR 1.48 (0.84 to 2.62)Hosoda (2016)33 HR 0.58 (0.25 to 1 1.38)CHozumi (2018)36 HR 2.69 (1.27 to 5.70) C?PR3-ANCAKagiyama (2015)32 HR 2.99 (1.52 to 5.86) HR 2.42 (1.23 to 4.76) Hozumi (2016)35 RR 1.79 (0.77 to 4.16)C?ANCANozu (2009)34 HR 0.60 (0.23 to 1 1.57)CPulmonary-cause mortality?MPO-ANCAHozumi (2018)36 RR 1.23 (0.74 to 2.07)C?PR3-ANCAHozumi (2016)35 RR 2.24 (0.95 to 5.28)CCTD incidence?ANA (1:40)Kang (2013)29 RR 7.11 (p=0.001) C?RF (20?IU/mL)Kang (2013)29 RR 2.26 (p=0.19)CMPA incidence?MPO-ANCAKagiyama (2015)32 RR 11.7 (3.15 to 43.5) CHosoda (2016)33 RR 61.0 (3.35 to 1108.5) CNozu (2009)34 RR 17.8 (1.02 to 311.6) CHozumi (2018)36 RR 99.4 Catechin (5.88 to 1679.7) CRadiological improvement?ANCANozu (2009)34 RR 1.53 (0.99 to 2.36)C Open in a separate window *Text in bold referring to a significant result and comparative numbers indicating data of IPF with vs without autoantibodies. ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic Catechin antibody; CCP, cyclic citrullinated peptide; CI, confidence interval; CTD, connective cells disease; IPF, idiopathic pulmonary fibrosis; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; RF, rheumatoid element; RR, risk percentage. The effect of MPO-ANCA on all-cause mortality was reported in three studies. One of these studies shown a significant result with HR of 2.69 (95% CI: 1.27 to 5.70) (eight deaths in 15 individuals with MPO-ANCA),36 whereas the results were non-significant and inconsistent in the others with HRs of 1.65 (95% CI: 0.97 to 2.80)32 and 0.58 (95% CI: 0.25 to 1 1.38) (five deaths in 12 individuals with MPO-ANCA),33 respectively. The effect of PR3-ANCA on all-cause mortality was reported in two studies.32.